J. Goldman & Co’s Alnylam Pharmaceuticals ALNY Stock Holding History

J. Goldman & Co’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-6,800	Closed	-$3.1M	–	553
2025 Q3	$3.1M	Buy	+6,800	New	+$2.77M	0.08%	245
2025 Q2	–	Sell	-21,000	Closed	-$5.67M	–	453
2025 Q1	$5.67M	Buy	+21,000	New	+$5.4M	0.14%	192
2024 Q4	–	Sell	-3,700	Closed	-$1.02M	–	444
2024 Q3	$1.02M	Sell	3,700 -46,600	-93%	-$12.1M	0.03%	294
2024 Q2	$12.2M	Buy	+50,300	New	+$7.94M	0.35%	95
2023 Q1	–	Sell	-20,000	Closed	-$4.75M	–	353
2022 Q4	$4.75M	Buy	+20,000	New	+$4.27M	0.23%	108

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

J. Goldman & Co's ALNY Position: Q2 2026 in Review

J. Goldman & Co opened a new position in Alnylam Pharmaceuticals (ALNY) in Q2 2026: 38,698 shares worth $11.6M. The stake represents 0.3% of the portfolio and ranks #92 among its holdings. This is a return to the name: J. Goldman & Co previously reported a position in ALNY as recently as Q4 2025.

J. Goldman & Co first reported a position in ALNY in Q1 2025 and has held it in 3 quarters since. The position peaked at $20M in Q1 2025. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

J. Goldman & Co held 38,698 shares of Alnylam Pharmaceuticals worth $11.6M as of Q2 2026.
Alnylam Pharmaceuticals was a new J. Goldman & Co position in Q2 2026.
Alnylam Pharmaceuticals made up 0.3% of J. Goldman & Co's portfolio in Q2 2026, its #92 holding.
J. Goldman & Co first reported a position in Alnylam Pharmaceuticals in Q1 2025 and has held it in 3 quarters since.
J. Goldman & Co's Alnylam Pharmaceuticals position peaked at $20M in Q1 2025.
790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.